TEV-48125 or placebo

DRUG2 trials

Sponsors

Otsuka Pharmaceutical Co., Ltd.

Conditions

Migraine

Phase 2

Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine

CompletedNCT03303092

Otsuka Pharmaceutical Co., Ltd.Migraine

Start: 2017-12-19End: 2019-11-22Updated: 2021-07-29

Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine

CompletedNCT03303079

Otsuka Pharmaceutical Co., Ltd.Migraine

Start: 2017-12-19End: 2019-11-30Updated: 2021-06-15

Related Papers

Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial

Headache The Journal of Head and Face Pain2024-09-021 citations

Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials.

2023-05-183 citations

Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials.

2023-04-201 citations

Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients

The Journal of Headache and Pain2022-02-0913 citations